- Home
- A vs ARGX Comparison
A vs ARGX Comparison
Compare A & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- A
- ARGX
- Stock Information
- Founded
- A 1999
- ARGX 2008
- Country
- A United States
- ARGX Netherlands
- Employees
- A N/A
- ARGX N/A
- Industry
- A Biotechnology: Laboratory Analytical Instruments
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- A Industrials
- ARGX Health Care
- Exchange
- A Nasdaq
- ARGX Nasdaq
- Market Cap
- A 38.6B
- ARGX 40.4B
- IPO Year
- A 1999
- ARGX 2017
- Fundamental
- Price
- A $109.69
- ARGX $590.06
- Analyst Decision
- A Buy
- ARGX Strong Buy
- Analyst Count
- A 13
- ARGX 20
- Target Price
- A $151.50
- ARGX $682.00
- AVG Volume (30 Days)
- A 2.2M
- ARGX 373.1K
- Earning Date
- A 05-28-2025
- ARGX 05-08-2025
- Dividend Yield
- A 0.90%
- ARGX N/A
- EPS Growth
- A 4.31
- ARGX N/A
- EPS
- A 4.36
- ARGX 12.78
- Revenue
- A $6,533,000,000.00
- ARGX $2,248,205,000.00
- Revenue This Year
- A $5.84
- ARGX $57.86
- Revenue Next Year
- A $6.23
- ARGX $31.90
- P/E Ratio
- A $25.16
- ARGX $43.50
- Revenue Growth
- A N/A
- ARGX 77.22
- 52 Week Low
- A $109.59
- ARGX $352.77
- 52 Week High
- A $155.35
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- A 25.39
- ARGX 44.86
- Support Level
- A $117.92
- ARGX $565.00
- Resistance Level
- A $124.43
- ARGX $598.06
- Average True Range (ATR)
- A 2.87
- ARGX 14.20
- MACD
- A -0.29
- ARGX -0.77
- Stochastic Oscillator
- A 0.30
- ARGX 40.42
About A Agilent Technologies Inc.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.